A recent preclinical study showed that combinatorial multilevel inhibition of PI3K/AKT/mTORC1 and CDK1 cell-cycle pathways is very effective in inhibiting DLBCL proliferation and overcoming drug resistance and has been suggested as an effective strategy in treating drug resistant DLBCLs with overactive AKT and CDK1 [338]. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.